CHRS
Price
$1.12
Change
+$0.11 (+10.89%)
Updated
Apr 17 closing price
Capitalization
129.8M
19 days until earnings call
KYMR
Price
$25.97
Change
+$0.95 (+3.80%)
Updated
Apr 17 closing price
Capitalization
1.69B
12 days until earnings call
Ad is loading...

CHRS vs KYMR

Header iconCHRS vs KYMR Comparison
Open Charts CHRS vs KYMRBanner chart's image
Coherus BioSciences
Price$1.12
Change+$0.11 (+10.89%)
Volume$3.01M
Capitalization129.8M
Kymera Therapeutics
Price$25.97
Change+$0.95 (+3.80%)
Volume$468.79K
Capitalization1.69B
CHRS vs KYMR Comparison Chart
Loading...
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KYMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CHRS vs. KYMR commentary
Apr 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CHRS is a Hold and KYMR is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 19, 2025
Stock price -- (CHRS: $1.12 vs. KYMR: $25.97)
Brand notoriety: CHRS and KYMR are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CHRS: 161% vs. KYMR: 62%
Market capitalization -- CHRS: $129.8M vs. KYMR: $1.69B
CHRS [@Biotechnology] is valued at $129.8M. KYMR’s [@Biotechnology] market capitalization is $1.69B. The market cap for tickers in the [@Biotechnology] industry ranges from $282.79B to $0. The average market capitalization across the [@Biotechnology] industry is $2.08B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CHRS’s FA Score shows that 0 FA rating(s) are green whileKYMR’s FA Score has 0 green FA rating(s).

  • CHRS’s FA Score: 0 green, 5 red.
  • KYMR’s FA Score: 0 green, 5 red.
According to our system of comparison, CHRS is a better buy in the long-term than KYMR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CHRS’s TA Score shows that 5 TA indicator(s) are bullish while KYMR’s TA Score has 5 bullish TA indicator(s).

  • CHRS’s TA Score: 5 bullish, 4 bearish.
  • KYMR’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, KYMR is a better buy in the short-term than CHRS.

Price Growth

CHRS (@Biotechnology) experienced а +50.90% price change this week, while KYMR (@Biotechnology) price change was +15.94% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.03%. For the same industry, the average monthly price growth was -13.25%, and the average quarterly price growth was -24.49%.

Reported Earning Dates

CHRS is expected to report earnings on Jul 31, 2025.

KYMR is expected to report earnings on Aug 01, 2025.

Industries' Descriptions

@Biotechnology (+7.03% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
KYMR($1.69B) has a higher market cap than CHRS($130M). CHRS YTD gains are higher at: -18.841 vs. KYMR (-35.446). CHRS has higher annual earnings (EBITDA): 60.9M vs. KYMR (-216.24M). KYMR has more cash in the bank: 489M vs. CHRS (126M). KYMR has less debt than CHRS: KYMR (87.8M) vs CHRS (270M). CHRS has higher revenues than KYMR: CHRS (267M) vs KYMR (47.1M).
CHRSKYMRCHRS / KYMR
Capitalization130M1.69B8%
EBITDA60.9M-216.24M-28%
Gain YTD-18.841-35.44653%
P/E Ratio4.48N/A-
Revenue267M47.1M567%
Total Cash126M489M26%
Total Debt270M87.8M308%
FUNDAMENTALS RATINGS
CHRS: Fundamental Ratings
CHRS
OUTLOOK RATING
1..100
41
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
46
P/E GROWTH RATING
1..100
38
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CHRSKYMR
RSI
ODDS (%)
Bullish Trend 5 days ago
90%
Bullish Trend 3 days ago
80%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
85%
Momentum
ODDS (%)
Bullish Trend 3 days ago
70%
Bullish Trend 3 days ago
79%
MACD
ODDS (%)
Bullish Trend 3 days ago
67%
Bullish Trend 3 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 3 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
71%
Bearish Trend 3 days ago
88%
Advances
ODDS (%)
Bullish Trend 5 days ago
72%
Bullish Trend 5 days ago
84%
Declines
ODDS (%)
Bearish Trend 16 days ago
86%
Bearish Trend 12 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
73%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
85%
View a ticker or compare two or three
Ad is loading...
CHRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KYMR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME26.780.53
+2.02%
GameStop Corp
AAPL196.982.71
+1.39%
Apple
SPY526.410.75
+0.14%
SPDR® S&P 500® ETF
TSLA241.37-0.18
-0.07%
Tesla
BTC.X84450.805000-444.945300
-0.52%
Bitcoin cryptocurrency

CHRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CHRS has been loosely correlated with XENE. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if CHRS jumps, then XENE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CHRS
1D Price
Change %
CHRS100%
+10.89%
XENE - CHRS
37%
Loosely correlated
+3.94%
SRRK - CHRS
33%
Loosely correlated
+3.33%
RIGL - CHRS
33%
Loosely correlated
+2.18%
KYMR - CHRS
33%
Loosely correlated
+3.80%
DNA - CHRS
33%
Poorly correlated
-2.97%
More

KYMR and

Correlation & Price change

A.I.dvisor indicates that over the last year, KYMR has been loosely correlated with CCCC. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if KYMR jumps, then CCCC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KYMR
1D Price
Change %
KYMR100%
+3.80%
CCCC - KYMR
63%
Loosely correlated
+13.64%
IMNM - KYMR
55%
Loosely correlated
+10.32%
NRIX - KYMR
55%
Loosely correlated
+4.49%
RVMD - KYMR
55%
Loosely correlated
+1.55%
RCKT - KYMR
54%
Loosely correlated
+2.93%
More